| |
| | Business Wire Business News: ArQule Initiates Phase 1 Trial with ARQ 171, Provides Enrollment Update on ARQ 501 and ARQ ... (Site not responding. Last check: ) |
 | | ARQ 197 is designed to block the activity of c-Met, a receptor tyrosine kinase that plays multiple key roles in human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis. |
 | | For example, ARQ 171, ARQ 501 and ARQ 197 may not demonstrate promising therapeutic effect; in addition, they may not demonstrate an appropriate safety profile in later stage or larger scale clinical trials as a result of known or as yet unanticipated side effects. |
 | | In addition, the planned timing of initiation and completion of clinical trials for ARQ 171, ARQ 501 and ARQ 197 are subject to the ability of the Company to enroll patients, enter into agreements with clinical trial sites and investigators, and other technical hurdles and issues that may not be resolved. |
| news.moneycentral.msn.com /provider/providerarticle.aspx?Feed=BW&Date=20061206&ID=6252233 (1404 words) |
|